



## The role of foot vessels in CLI



Roberto Ferraresi  
Peripheral Interventional Unit

**HUMANITAS**  
GAVAZZENI

Bergamo – Italy

[www.robtoferraresi.it](http://www.robtoferraresi.it)

# Disclosure

Roberto Ferraresi, MD

I have the following potential conflicts of interest to report: consulting, travel reimbursement, teaching courses, training, proctoring:

- **Medtronic**
- **Boston Scientific**
- **Abbott**
- **LimFlow**
- **Terumo**
- **Cook**
- **Biotronik**


**No conflict with this lecture**


# The role of foot vessels in CLI

1. **Foot vessel disease: prevalence & risk factors**
2. **Role of foot vessel disease in CLI: innocent bystander or leading actor?**
3. **Treatable non-calcified foot vessel occlusive disease**
4. **Untreatable calcified foot vessel occlusive disease: what can we do?**

# Obstructive disease distribution in a series of 1624 pts with CLI (RTF 5-6)

“Below the Ankle Peripheral Artery Disease” Ferraresi R et Al  
PanVascular Medicine II edition, Lanzer P ed, Springer-Verlag,  
Heidelberg, 2014





## FOOT VESSEL CLASSIFICATION


We considered 4 big foot vessels:

1. retromalleolar posterior tibial artery
2. dorsalis pedis artery
3. lateral plantar artery
4. medial plantar artery


Plantar arch was considered **separately**, as the distal arch originating from lateral plantar artery, giving the forefoot distribution system and connecting to dorsalis pedis artery through the 1<sup>st</sup> perforating branch

## Obstructive disease distribution in a series of 1624 pts with CLI (RTF 5-6)

“Below the Ankle Peripheral Artery Disease” Ferraresi R et Al  
PanVascular Medicine II edition, Lanzer P ed, Springer-Verlag,  
Heidelberg, 2014




Percentage of BTA diseased vessels  
(arch excluded) according to risk factors







# Obstructive disease distribution in a series of 1624 pts with CLI (RTF 5-6)

“Below the Ankle Peripheral Artery Disease” Ferraresi R et Al  
PanVascular Medicine II edition, Lanzer P ed, Springer-Verlag,  
Heidelberg, 2014



### Arch disease according to risk factors





**1° Conclusion:**  
**BTA disease: prevalence & risk factors**

- 1. Foot vessel disease is present in >70% of patients with CLI**
- 2. Foot vessel disease is particularly represented in DM-ESRD pts**



# The role of foot vessels in CLI

1. **Foot vessel disease: prevalence & risk factors**
2. **Role of foot vessel disease in CLI: innocent bystander or leading actor?**
3. **Treatable non-calcified foot vessel occlusive disease**
4. **Untreatable calcified foot vessel occlusive disease: what can we do?**

**Disease distribution in a series of 1915 with PAD  
and a complete angiographic study of foot vessels**

<b><i>PAD symptoms</i></b>	<b><i>N°</i></b>	<b><i>%</i></b>
<i>Asymptomatic</i>	6	0.3
<i>Claudication</i>	177	9.2
<i>Ischemic Rest Pain</i>	90	4.7
<i>Ulceration or Gangrene</i>	1642	85.7
<i>Total</i>	1915	100

“Below-the-ankle vessel disease in CLI patients: innocent bystander or leading actor?” Ferraresi R et Al, submitted for publication 2015




<b>Risk Factor for CLI</b>	<b>OR (p)</b>
<b>Above the ankle vessel disease</b>	<b>1,20 (&lt;.05)</b>
<b>Foot vessel disease (arch excluded)</b>	<b>1,58 (&lt;.05)</b>
<b>Arch = small vessel disease</b>	<b>7,83 (&lt;.01)</b>


Risk Factor for CLI	OR (p)
Above the ankle vessel disease	1,20 (<.05)



Risk Factor for CLI	OR (p)
Foot vessel disease	1,58 (<.05)



Risk Factor for CLI	OR (p)
Arch = small vessel disease	7,83 (<.01)




Risk Factor for CLI	OR (p)
Above the ankle vessel disease	1,20 (<.05)



www.robtoferraresi.it

Risk Factor for CLI	OR (p)
Foot vessel disease	1,58 (<.05)



Risk Factor for CLI	OR (p)
Arch = small vessel disease	7,83 (<.01)





**2° Conclusion:**  
 Role of foot vessel disease in CLI:  
 innocent bystander or leading actor?

1. The disease of every above-the-ankle vessel segment has a weak association with CLI: we need many of them to get CLI
2. Foot vessel disease has the strongest association with CLI, particularly the small vessel disease of the arch (*the tiger of CLI!*)


# The role of foot vessels in CLI


1. **Foot vessel disease: prevalence & risk factors**
2. **Role of foot vessel disease in CLI: innocent bystander or leading actor?**
3. **Treatable non-calcified foot vessel occlusive disease**
4. **Untreatable calcified foot vessel occlusive disease: what can we do?**





Above the ankle vessel disease






**Below the  
ankle vessel  
disease**




**Above the ankle vessel  
disease treatment**

**basal**



**Below the ankle vessel  
disease treatment**




**after PTA**

4008 WL: 2048

De




FRAME  
A

Direct blood flow on the dorsal and plantar side of the foot



6 months later





**3° Conclusion:**  
**Treatable non-calcified foot vessel disease**

**In my opinion we cannot treat CLI without considering and facing in every patient foot vessel disease**



# The role of foot vessels in CLI

1. **Foot vessel disease: prevalence & risk factors**
2. **Role of foot vessel disease in CLI: innocent bystander or leading actor?**
3. **Treatable non-calcified foot vessel occlusive disease**
4. **Untreatable calcified foot vessel occlusive disease: what can we do?**

# **Meta-analysis of the Clinical Effectiveness of Venous Arterialization for Salvage of Critically Ischaemic Limbs**

**X.W. Lu,<sup>1</sup> M.M. Idu,<sup>1</sup> D.T. Ubbink<sup>1,2</sup> and D.A. Legemate<sup>1\*</sup>**

**Eur J Vasc Endovasc Surg 31, 493–499 (2006)**

**Objective.** The aim of this study is to assess the clinical effectiveness of venous arterialization in patients with critical limb ischaemia not reconstructable by conventional bypass.

**Design.** Meta-analysis of observational studies.


**Results.** A total of 56 studies were selected. No RCTs were identified. Seven patient series, comprising 228 patients, matched the selection criteria. Overall 1-year foot preservation was 71% (95% CI: 64–77%) and 1-year secondary patency was 46% (95% CI: 39–53%). The large majority of patients in whom major amputation was avoided experienced successful wound healing, disappearance of rest pain and absence of serious complications.

**Conclusion:** on the basis of limited evidence, venous arterialization may be considered as a viable alternative before major amputation is undertaken in patients with 'inoperable' chronic critical leg ischaemia.

**Patient 1**








**Patient 2**



1  
11




VENOUS ART 01


Sep 02 2014  
09:24:33 AM

WW: 256WL: 128





WW: 256 WL: 128



ARTERIALIZATION 01E

Sep 16 2014  
09:13:12

(Flit 3)

Seq: 3  
FRAME = 40 / 48  
MASK = 2



VENOUS ART 01E

Sep 02 2014  
09:31:12

(Flit 3)

Seq: 4  
FRAME = 54 / 58  
MASK = 2

008 WL: 2048



VENOUS ART 01E

Sep 02 2014  
09:33:33

(Flit 8)

Seq: 1  
FRAME = 19 / 8

L: 128



VENOUS ART 01E

Sep 02 2014  
09:34:09

(Flit 8)

Seq: 7  
FRAME = 23 / 27

58 WL: 128



3.0 X 120 mm 14 atm



3.0 X 20 mm 26 atm

: 256WL; 128

Seq  
FRAME = 14

VENOUS ART 0  
Sep 02 2011  
10:03:5

(FIL 8)

Seq 1  
FRAME = 5/

: 256WL; 128



VENOUS ART 01

Sep 02 2014  
10:12:09

(Flt 5)


Seq: 20  
FRAME = 6 / 107  
MASK = 2

WW: 4098WL: 2048



## **Patient 3**


Courtesy Dr. Cesare Massa Saluzzo  
Pavia - Italy




13

Courtesy Dr. Cesare Massa Saluzzo  
Pavia - Italy

43




Courtesy Dr. Cesare Massa Saluzzo  
Pavia - Italy




24%

Arch disease according to risk factors




Risk Factor for CLI	OR (p)
Arch = small vessel disease	7,83 (<.01)



24%



**4° Conclusion:**  
**Untreatable calcified foot disease**



**In my opinion the arterialization of the venous system of the foot is the only hope that we have today for limb salvage in CLI patients with the calcific small vessel disease of the arch (*the tiger of CLI!*).**

**But we need more studies....**